Global Artificial Insemination Market is segmented By Type (Intrauterine Insemination, Intracervical Insemination, Intratubular Insemination, Others) By Product Type (IUI Catheters, Insemination Kits, Test Kits, Accessories) By Source Type (Homologous Artificial Insemination, Heterologous Artificial Insemination) By End Users (Hospitals & Clinics, Fertility centers, Homecare Setting, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global artificial insemination market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Artificial inseminiation is a type of fertility treatment that involves inserting the sperm directly into the women’s womb. Also known as intrautetine insemination, this procedure is one of the common ways of overcoming infertilty that is caused due to unknown reasons, cerivcal issues, low sperm counts, endometriosis etc. Artificial insemination can be done by using the partners sperm or a donar sperm, which is then processed in the ferility centers and then implanted into the uterus using a fine catheter.
This process is done immediately after the phase of ovulation in women. A few attempts are necessary before successful conception. During the process, several instruments/devices are used to assist the procedure which include, “speculum” a device used to open the vagina during the insemination process, “cathether” a device used to insert the sperm into the uterus, “ovulation testing kits” to test the menstrual cycle phase in women, especially to know the ovulation period for successful implantation etc.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Market Size | 2022-2031 |
| Market Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Type, Product Type, Source Type and End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Rising prevalance of Infertility
Infertility has been a major concern in this modern era, there are several factors which causes infertility and are mainly attributable to physical factors such as ovulation disorders like PCOS (Polycystic Ovary Sydrome), unknown uterine damage, endometriasis, low quality sperm, male sexual dysfunction. Moreover the fast-paced, demanding nature of modern living has resulted in higher stress levels for many people.
Chronic stress has been linked to endocrine system abnormalities, which impact the balance of reproductive hormones such cortisol and progesterone. Stress can disrupt menstrual cycles and ovulation in women, and also affect sperm production and quality in males, contributing to infertility. Out of several methods for infertility treatment, artificial insemination is most widely prefered for minor conditions and is also non-invasive. With the rising infertility rates, the demand for artificial insemination is expected to rise in the forecast period.
For instance, on April 4, 2023, according to the data reported by World Health Organization, approximately 1 in every 6 people suffer from infertility in their life time with a life time prevalance of 17.5% and periodic prevalence of 12.6%.
On July 18, 2022, an article published in the National Center for Biotechnology Information has predicted that in the upcoming decade, fertility due to assisted reproductive technologies among U.S. population will rise from 1.29% in 2020 to 1.97% in 2030 and 2.64% in 2040.
If the pharmacological treatement has failed to treat infertility, IUI (intrauterine Insemination) is selected as the first line treatment option. Although In-Vitro Fertilization is being chosen widely these days, it is expensive and low-middle income countries and middle income countries cannot afford IVF treatments. IUI is a cost-friendly option and is widely followed for mild and idiopathic infertility cases.
Moreover, rising advancements in the infertility treatment, rising approval of home-based products, rising same-sex couples opting for IUI treatments to become parents etc. are driving the market in the forecast period.
Restraints
Factors such as lack of skilled professionals, availability of alternate options etc are expected to restrain the market growth.
Segment Analysis
The global artificial insemination market is segmented based on product type, type, end user and region.
The intrauterine insemination in the type segment accounted for approximately 54.6% of the global artificial insemination market share
Among all the artificial insemination types, intrauterine insemination is widely perfomed method due to its high success rates and is most efficient technique as compared to other procedures. In intrauterine insemination, the washed and concentrated sperm is directly inserted into the uterus bypassing the cervix to fecilitate fertilization. This is done when the women is in ovulatory phase of menstrual cycle. During ovulation the success rate of fertilization with assisted insemination is higher because the sperm is delivered near to the location of fertilization. Intrauterine insemination is a main stay option for unknown infertility caused in both male and female.
For instance, according to Cryos International Clinic of Denmark, IUI (Intrauterine insemination) has the highest success rate as compared to the ICI (Intracervical insemination) as the sperm is placed closer to the egg, the chances of fertilization is higher than any other artificial insemination procedure.
On April 23, 2022, a clinical study results published in the National Center for Biotechnology Information has stated that intrauterine insemination is superior to intracervical insemination when a donor sperm is used. Although the cost variation is seen between two, the success rate is higher with IUI which makes the cost factor almost negligible. The study has also suggest that, as IUI is perfomed in leu with the natural menstrual cycle, it should be adopted as a first line treatment option.
Geographical Analysis
North America is expected to dominate the market with 43.3% share in the Global artificial insemination Market
North America is expected to dominate the market due to its advanced healthcare infrastructure and well equipped fertility treatment centers. Moreover with the rising infertility rates and increasing demand for fertility treatments have been playing a significant role for the highest market share of north America. In North America, the leading countries especially U.S. ranks 3rd in the total global population with highest total and periodic prevalance of infertility. In addition the easy accessibility of fertility treatment services, product launches and availability of home based products are some factors contributing to the major market share of North America.
For instance, on April 4, 2023, according to the data reported by World Health Organization, the American region has the life time prevalance of infertility i.e., 20% and the periodic prevalance of 4.0-15.7%,which is higher than the global average of 17.5% life time prevalance and 12.7% of periodic prevalance.
On December 6 2023, US Food and Drug Administration has approved the first at-home based artificial insemination kit Mosie Baby the innovation of Mosie Inc. Moise baby is a intravaginal insemination kit available over the counter for a price of $129 all across U.S. The kit is helpful for those who cannot concive by sexual interaction.
In December 2023, US Food and Drug Administration has approved the use of at-home sterile artificial insemination kit PherDel developed by PherDal Fertility Science. An U.S. based company. Upon approval, the company has been focusing on production of these kits to supply to millions of citizens who are trying to concieve. These recent product approvals are expected to increase the market value of North America in the current year and in the forecasted period.
Competitive Landscape
The major players in the artificial insemination market include GYNEMED GmbH & Co. KG, CooperSurgical, Inc., gynotec, Rocket Medical plc., Cook, Mosie Inc, Pride Angel, Fridababy, LLC., Allwin Medical Devices, and Kitazato Corporation. among others.
COVID-19 Impact Analysis
The global market for artificial insemination was affected by the COVID-19 pandemic. During the pandemic, the fertility centers have limited the treatment of infertility including IUI procedures due to surge in virus infected patients. Majority of healthcare providers diverted towards the care of infected patients and there was a reduction in elective procedures and treatments. Due to ban on international travel, the medical tourism for IUI procedures were declined.
For instance, On November 11, 2022, a study published in the Journal MDPI has stated that the Covid pandemic has greatly affected the infertility treatments all across the world. In comparison with the pre-pandemic years of 2018 and 2019, the number of IUI procedures performed during the pandemic in 2020 were greatly reduced.
Why Purchase the Report?
- To visualize the global artificial insemination market segmentation based on type, product type, end user, and country, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of artificial insemination market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global artificial insemination market report would provide approximately 70 tables, 64 figures, and 187 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
